Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Injection for treating coronary heart disease and cerebral infarction

A technology of cerebral infarction and injection, applied in the field of plant materials, can solve the problems of general curative effect, incompatibility, and slow onset of effect

Active Publication Date: 2007-02-07
西安万隆制药股份有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, the western medicines for the treatment of cerebral infarction mainly include: tissue plasminogen activator and recombinant tissue plasminogen activator, defibrase, urokinase, heparin, warfarin, and low molecular weight heparin. Certain limitations, the onset of effect is also slow, and the curative effect is not significant enough; oral preparations in Chinese patent medicines mainly include Huatuozaizao pills, Tongpuluji, Naoan capsules, etc. The course of the disease develops regularly, and the injections include Danshen injection, puerarin injection, safflower injection, compound Danshen injection, etc., but most of them are early injection products, the quality control is not ideal, the curative effect is general, and adverse reactions often occur in clinical practice. significantly restricted

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Injection for treating coronary heart disease and cerebral infarction
  • Injection for treating coronary heart disease and cerebral infarction
  • Injection for treating coronary heart disease and cerebral infarction

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0032] Taking the production of 1000 injections of the present invention as an example, the used bulk drug and auxiliary materials and their weight ratios are:

[0033] Panax notoginseng 2500g

[0034] Hawthorn leaves 1250g

[0035] Mannitol 123.75g

[0036] In the present embodiment, the percentage by weight of each Chinese medicine raw material is:

[0037] Notoginseng 66.67%

[0038] Hawthorn Leaf 33.33%

[0039] The dosage of mannitol is 3.3% of Panax notoginseng and hawthorn leaves.

[0040] Its preparation method is as follows

[0041] 1. Extraction of active ingredients

[0042] (1) Extraction of active ingredients of Panax notoginseng

[0043] Take 2500g of Radix Notoginseng medicinal material, pulverize, sieve, extract 3 times with 10 times the amount of 75% ethanol, combine the three extracts, filter, recover the ethanol until it is nearly dry, add 95 % ethanol, refrigerated for 12 hours, filtered, recovered ethanol, concentrated to no alcohol smell, added 80...

Embodiment 2

[0055] Taking the production of 1000 injections of the present invention as an example, the used bulk drug and auxiliary materials and their weight ratios are:

[0056] Panax notoginseng 2625g

[0057] Hawthorn leaves 1125g

[0058] Mannitol 123.75g

[0059] In the present embodiment, the percentage by weight of each Chinese medicine raw material is:

[0060] Panax notoginseng 70%

[0061] Hawthorn Leaf 30%

[0062] The dosage of mannitol is 3.3% of Panax notoginseng and hawthorn leaves.

[0063] Its preparation method is identical with embodiment 1. Each stick weighs 250mg, and each gram contains 15g of traditional Chinese medicine raw materials.

[0064] Usage: Intravenous drip, 1 to 2 tubes at a time, once a day. Before use, fully dissolve it with 5mL water for injection, and then dilute it with 500ml sodium chloride injection or 5% glucose injection.

Embodiment 3

[0066] Taking the production of 1000 injections of the present invention as an example, the used bulk drug and auxiliary materials and their weight ratios are:

[0067] Panax notoginseng 1125g

[0068] Hawthorn leaves 2625g

[0069] Mannitol 123.75g

[0070] In the present embodiment, the percentage by weight of each Chinese medicine raw material is:

[0071] Panax notoginseng 30%

[0072] Hawthorn Leaf 70%

[0073] The dosage of mannitol is 3.3% of Panax notoginseng and hawthorn leaves.

[0074] Its preparation method is identical with embodiment 1. Each stick weighs 250mg, and each gram contains 15g of traditional Chinese medicine raw materials.

[0075] Usage: Intravenous drip, 1 to 2 tubes at a time, once a day. Before use, fully dissolve it with 5mL water for injection, and then dilute it with 500ml sodium chloride injection or 5% glucose injection.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Disclosed is an injection for treating coronary heart disease and cerebral infarction which is prepared from the raw material (by weight ratio) of notoginseng 70-30%, haw leaf 30-70% through the conventional preparing processes. The injection may also contains mannitol as the adjuvant.

Description

technical field [0001] The invention belongs to the technical field of medical preparations containing raw materials or their reaction products with unknown structures, and specifically relates to materials derived from plants. Background technique [0002] Coronary heart disease Angina pectoris is a common cardiovascular disease, more common in middle-aged and elderly people. With the aging of the population, it has become one of the main diseases that seriously endanger human physical and mental health. Coronary heart disease angina pectoris is a clinical syndrome caused by coronary atherosclerosis leading to vascular lumen stenosis, coronary insufficiency, and myocardial acute and transient ischemia and hypoxia. Coronary heart disease angina pectoris is an epidemic in industrialized countries, and has become the most common heart disease in European and American countries. In recent years, the incidence rate of coronary heart disease in my country has been increasing si...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): A61K36/734A61K36/258A61K9/08A61P9/10
Inventor 马耀茹
Owner 西安万隆制药股份有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com